BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cooke GS. Scaling-up HCV treatment to achieve WHO targets by 2030. Trop Med Int Health 2017;22:372-4. [DOI: 10.1111/tmi.12837] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Tenner L, Melhado TV, Bobadilla R, Turner BJ, Morgan R. The Cost of Cure: Barriers to Access for Hepatitis C Virus Treatment in South Texas. J Oncol Pract 2019;15:61-3. [PMID: 30668219 DOI: 10.1200/JOP.18.00525] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
2 Jain MK, Thamer M, Therapondos G, Shiffman ML, Kshirsagar O, Clark C, Wong RJ. Has Access to Hepatitis C Virus Therapy Changed for Patients With Mental Health or Substance Use Disorders in the Direct-Acting-Antiviral Period? Hepatology 2019;69:51-63. [PMID: 30019478 DOI: 10.1002/hep.30171] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
3 Ali S, Ur-Rehman T, Ali M, Haque S, Rasheed F, Lougher E, Nawaz MS, Paudyal V. Improving access to the treatment of hepatitis C in low- and middle-income countries: evaluation of a patient assistance programme. Int J Clin Pharm 2021;43:958-68. [PMID: 33247820 DOI: 10.1007/s11096-020-01202-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sghaier I, Brochot E, Loueslati BY, Almawi WY. Hepatitis C virus protein interaction network for HCV clearance and association of DAA to HCC occurrence via data mining approach: A systematic review and critical analysis. Rev Med Virol 2019;29:e2033. [PMID: 30614131 DOI: 10.1002/rmv.2033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]